Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effects and Safety of GEMOX Combined With Donafenib and Tislelizumab in Advanced Biliary Tract Carcinoma：a Prospective, Single-arm, Multi-center Phase II Study

NCT05668884 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.

NCT NCT05668884
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05668884 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effects and Safety of GEMOX Combined With Donafenib and Tislelizumab in Advanced Biliary Tract Carcinoma：a Prospective, Single-arm, Multi-center Phase II Study
Lead sponsor
Fudan University
Phase
Phase 2
Overall status
Recruiting
Start date
October 18, 2022
Completion date
March 31, 2027
Enrollment
93 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

biliary tract carcinoma